Treating dyslipidaemia in the setting of diabetes mellitus and cardiovascular disease: a less commonly perceived therapeutic perspective in clinical practice.
Diabetes mellitus and cardiovascular disease are being managed more belligerently in recent times, with multifactorial cardiovascular risk reduction being the focus of therapeutic interventions. We review some of the caveats to be exercised in the treatment of these patients that are pertinent to clinicians in daily clinical practice.
Varughese
G I
GI
Department of Diabetes & Endocrinology, University Hospital of North Staffordshire, Stoke-on-Trent, UK. georgeiv@doctors.org.uk
Scarpello
J H B
JH
D051544:Cytochrome P-450 CYP3A; D065607:Cytochrome P-450 Enzyme Inhibitors; D003925:Diabetic Angiopathies / Q000150:complications*; D050171:Dyslipidemias / Q000150:complications / Q000188:drug therapy*; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D012307:Risk Factors
D065607:Cytochrome P-450 Enzyme Inhibitors; D004791:Enzyme Inhibitors; D000960:Hypolipidemic Agents; D051544:Cytochrome P-450 CYP3A; C510163:CYP3A4 protein, human